Neurotech
Neurotech Pharmaceuticals is a private biotech that developed ENCELTO, the first FDA-approved encapsulated cell therapy for Macular Telangiectasia Type 2 (MacTel), delivering sustained Ciliary Neurotrophic Factor via a single intraocular implant to protect photoreceptors in adult patients.
- Company typePrivate
- Founded1995
- HeadquartersLincoln, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Neurotech does
Neurotech Pharmaceuticals, Inc. is a privately-held biotechnology company founded in 1995 and headquartered in Cumberland, Rhode Island, with a commercial office in Needham, Massachusetts, and 51-100 employees. The company develops sight-saving therapeutics for chronic retinal diseases, with its sole FDA-approved product, ENCELTO (revakinagene taroretcel-lwey), approved in March 2025 as the first and only treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel), a rare bilateral retinal disease causing progressive photoreceptor loss and central vision impairment.
The company's core technology is its proprietary Encapsulated Cell Therapy (ECT) platform, which encapsulates genetically engineered human retinal cells within a semi-permeable membrane. Once implanted in the vitreous, the capsule creates an immune-protective microenvironment and continuously secretes Ciliary Neurotrophic Factor (CNTF) — a well-studied neuroprotective protein — directly to the retina for greater than two years from a single surgical application. This sustained-delivery architecture differentiates ENCELTO from conventional intravitreal or sub-retinal injection therapies that require frequent re-administration. The platform is supported by Orphan-Drug Designation (2012), Fast Track Designation (2018), Priority Review (2024), and a permanent reimbursement J-Code (J3403, effective October 1, 2025).
Neurotech operates a specialty pharmaceutical commercial model, selling ENCELTO directly to trained retina specialists via field sales representatives, medical science liaisons, and field reimbursement directors, with distribution through physician-administered specialty channels in the United States only. The company is controlled by the Lowy family, with a Board including former Johnson & Johnson CEO Alex Gorsky (Lead Director) and Wilmer Eye Institute Director Peter J. McDonnell, M.D. Revenue derives entirely from ENCELTO product sales at premium orphan-drug pricing levels, and the company has historically funded operations through venture financing, including a $35 million round in 2006 led by Burrill & Company.
Neurotech firmographics
Firmographics- Name
- Neurotech
- Legal name
- Neurotech Pharmaceuticals, Inc.
- Website
- https://neurotechpharmaceuticals.com
- Company type
- Private
- Founded year
- 1995
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Neurotech Pharmaceuticals is a private biotech that developed ENCELTO, the first FDA-approved encapsulated cell therapy for Macular Telangiectasia Type 2 (MacTel), delivering sustained Ciliary Neurotrophic Factor via a single intraocular implant to protect photoreceptors in adult patients.
- Ownership category
- akta.pro rank
Neurotech industry classification
Industry- Product category
- Ophthalmic Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Infusion Sets, Catheters & Pump Consumables (HLAHAIAH)
- akta.pro secondary industries
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Ophthalmic Regeneration (cornea/retina) (HLAAAGAK)
Keywords
Where Neurotech is headquartered
LocationHeadquarters
- HQ city
- Lincoln
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Neurotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Product Sales: Revenue from the sale of ENCELTO (revakinagene taroretcel-lwey) for the treatment of Macular Telangiectasia Type 2 (MacTel). The product is administered via a surgical procedure and likely commands premium pricing as a novel cell therapy for a rare disease with no prior approved treatments.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Neurotech product offering
Product offeringCore offering
Neurotech Pharmaceuticals develops and commercializes ENCELTO (revakinagene taroretcel-lwey), an FDA-approved encapsulated cell therapy implant for treating adults with idiopathic Macular Telangiectasia Type 2 (MacTel). The product is built on the company's proprietary Encapsulated Cell Therapy (ECT) Platform, which encapsulates genetically engineered human retinal cells within a semi-permeable membrane to continuously deliver Ciliary Neurotrophic Factor (CNTF) to the retina for greater than two years from a single surgical implantation. ENCELTO is the first and only FDA-approved treatment for MacTel Type 2, a rare bilateral retinal disease causing progressive photoreceptor loss and central vision impairment.
Product overview
Neurotech Pharmaceuticals is a private biotech company developing a singleFDA-approved product, ENCELTO (revakinagene taroretcel-lwey), delivered via its proprietary Encapsulated Cell Therapy (ECT) platform. The ECT platform is a cell-based drug delivery technology that encapsulates genetically engineered human retinal cells within a semi-permeable membrane, enabling sustained, long-term delivery of therapeutic proteins (specifically Ciliary Neurotrophic Factor, or CNTF) to the retina. ENCELTO is indicated for the treatment of adults with idiopathic Macular Telangiectasia Type 2 (MacTel), a chronic retinal disease. The therapy is administered via a single intraocular implant designed to deliver CNTF for greater than two years following a single application.
Differentiator
Problem solved
Functional benefit
Brands
- ENCELTO: FDA-approved treatment for Macular Telangiectasia Type 2 (MacTel), also known by its generic name revakinagene taroretcel-lwey
Products and services
- ENCELTO (revakinagene taroretcel-lwey) ENCELTO is an FDA-approved encapsulated cell therapy implant indicated for the treatment of adults with idiopathic Macular Telangiectasia Type 2 (MacTel), a rare bilateral retinal disease causing progressive loss of central vision. The implant contains genetically engineered human retinal cells encapsulated within a semi-permeable membrane that continuously secretes Ciliary Neurotrophic Factor (CNTF) into the vitreous, with the goal of slowing photoreceptor loss and disease progression for greater than two years following a single intraocular surgical implantation.
Quantifiable outcome
- First FDA-approved treatment for MacTel Type 2
- +2 more outcomes
Companies that use Neurotech
Customer profileSegments1 record
Ideal customer profiles1 record
Neurotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Neurotech partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor.
- Prevent BlindnessminorPatient advocacy organization providing community resources and support for patients with eye diseases. Neurotech references this organization as a community resource for MacTel patients.
- National Organization for Rare Disorders (NORD)minorRare disease advocacy organization providing support and resources for patients with rare conditions including MacTel. Listed as a community resource for patients.
- Foundation Fighting BlindnessminorNonprofit dedicated to research for treatments and cures for blinding retinal diseases. Listed as a community resource for MacTel patients.
- American Academy of OphthalmologyminorProfessional medical association for ophthalmologists. Listed as a community resource for patient education on eye health.
- The Carroll Center for the BlindminorOrganization providing services and support for blind and visually impaired individuals. Listed as a community resource for MacTel patients.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Neurotech competitors and assessment
Company assessmentBroad incumbents
- Iveric Bio (Astellas): Retinal disease biotech (acquired by Astellas in 2023) with FDA-approved therapy for geographic atrophy. Comparable to Neurotech as a commercialized retinal therapeutics company; now part of a larger strategic owner.
- Gyroscope Therapeutics (Novartis): Gene therapy company (acquired by Novartis in 2022) focused on geographic atrophy and inherited retinal diseases. Comparable as a retinal-disease biotech using novel delivery modalities; larger strategic owner now provides competitive context.
Emerging players
- MeiraGTx Holdings: Clinical-stage gene therapy company with capabilities in ocular gene therapy (e.g., AAV-RPGR for X-linked retinitis pigmentosa) and in-house GMP manufacturing. Comparable to Neurotech in deploying novel genetic and cell-based therapeutics to the eye.
- Adverum Biotechnologies: Clinical-stage gene therapy company developing single-administration intravitreal therapies for wet AMD and diabetic retinopathy. Comparable to Neurotech in deploying novel ocular drug-delivery modalities for chronic retinal disease.
- GenSight Biologics: Clinical-stage gene therapy company developing neuroprotective therapies for retinal degenerative diseases (e.g., Leber hereditary optic neuropathy). Comparable in deploying novel ocular therapeutics for rare retinal/optic nerve indications.
- ProQR Therapeutics: Clinical-stage RNA therapeutics company targeting inherited retinal diseases such as Leber congenital amaurosis and retinitis pigmentosa. Comparable in developing novel modalities for rare, vision-threatening retinal indications.
- REGENXBIO: Gene therapy company with FDA-approved ocular gene therapy (ABBV-RGX-314 partnership with AbbVie) for wet AMD and diabetic retinopathy. Comparable as a developer of novel one-time ocular therapeutics for retinal disease.
Direct peers
- Apellis Pharmaceuticals: Commercial-stage biotech developing therapeutics for retinal diseases (geographic atrophy, AMD). Comparable to Neurotech as a recently commercialized, specialty ophthalmology biotech targeting retinal indications with novel mechanisms.
- Lineage Cell Therapeutics: Clinical-stage cell therapy company developing allogeneic cell transplants for ophthalmology, neurology, and oncology. Directly comparable to Neurotech's ECT platform in using encapsulated or transplanted cells to deliver therapeutic proteins to retinal tissue.
- Kodiak Sciences: Clinical-stage retinal therapeutics company developing novel biological agents (antibody biopolymer conjugates) for retinal vascular and inflammatory diseases. Comparable as a venture-backed biotech focused on innovative retinal drug delivery and ophthalmology indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Neurotech social profiles
Digital presenceNeurotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neurotech leadership team
Management profileNumber of profiles
Profiles12 records
Neurotech funding detail
Funding detailFunding overview
Funding rounds2 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neurotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neurotech
What does Neurotech do?
Neurotech Pharmaceuticals develops and commercializes ENCELTO (revakinagene taroretcel-lwey), an FDA-approved encapsulated cell therapy implant for treating adults with idiopathic Macular Telangiectasia Type 2 (MacTel). The product is built on the company's proprietary Encapsulated Cell Therapy (ECT) Platform, which encapsulates genetically engineered human retinal cells within a semi-permeable membrane to continuously deliver Ciliary Neurotrophic Factor (CNTF) to the retina for greater than two years from a single surgical implantation. ENCELTO is the first and only FDA-approved treatment for MacTel Type 2, a rare bilateral retinal disease causing progressive photoreceptor loss and central vision impairment.
Is Neurotech a public or private company?
Neurotech is a private company. It is classified as family owned and is currently operating.
When was Neurotech founded?
Neurotech was founded in 1995. It employs 51 to 100 people.
Where is Neurotech based?
Neurotech is headquartered in Lincoln, United States, in the North America region.
How does Neurotech make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Neurotech's main competitors?
Broad incumbents on record are Iveric Bio (Astellas) and Gyroscope Therapeutics (Novartis). Emerging players are MeiraGTx Holdings, Adverum Biotechnologies, GenSight Biologics, ProQR Therapeutics and REGENXBIO. Direct peers are Apellis Pharmaceuticals, Lineage Cell Therapeutics and Kodiak Sciences.
Does Neurotech have an API?
No public API is recorded for Neurotech.
What industry is Neurotech in?
Neurotech's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAHAIAH, Infusion Sets, Catheters & Pump Consumables, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 3841.